Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PCS499 · CTP-499

Small molecule · developed by Processa Pharmaceuticals

Phase 2 Most advanced trial (none active)
PCSA Developer
1 Registered trials

What is PCS499?

PCS499 is a deuterated analog of pentoxifylline.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CTP-499, deuterated pentoxifylline analog
Drug type
Small molecule
Therapy area
Dermatology
Developer
Processa Pharmaceuticals (PCSA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
FLV771E8ZV

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03698864 Phase 2 Necrobiosis Lipoidica Completed PCSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Necrobiosis Lipoidica

More from Processa Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PCSA page.

Follow PCSA, the company behind PCS499

See PCSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PCSA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.